Eyenovia (EYEN) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free EYEN Stock Alerts $0.75 -0.07 (-8.54%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 3:35 AM | americanbankingnews.comEyenovia, Inc. to Post FY2028 Earnings of $0.04 Per Share, Brookline Capital Management Forecasts (NASDAQ:EYEN)May 17 at 12:53 PM | msn.comEyenovia, Inc. (NASDAQ:EYEN) Q1 2024 Earnings Call TranscriptMay 16 at 10:31 AM | finance.yahoo.comEyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...May 16 at 8:56 AM | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Eyenovia (NASDAQ:EYEN)HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Eyenovia in a report on Thursday.May 15, 2024 | globenewswire.comEyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and ClobetasolMay 14, 2024 | globenewswire.comEyenovia to Report First Quarter 2024 Results on Wednesday, May 15thMay 12, 2024 | za.investing.comEarnings call: NovaBay reports record Avenova sales, eyes dry eye marketMay 4, 2024 | cnn.comEyenovia, Inc.April 26, 2024 | finanznachrichten.deEyenovia, Inc.: Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic SuspensionApril 25, 2024 | globenewswire.comEyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic SuspensionApril 17, 2024 | msn.comEyenovia (EYEN) Price Target Decreased by 24.29% to 7.21April 10, 2024 | investing.comEyenovia explores strategic alternatives amid new product developmentsApril 8, 2024 | marketwatch.comEyenovia Shares Fall More Than 14% After Company Says It Is Exploring SaleApril 8, 2024 | marketwatch.comEyenovia Explores Options, Including Potential SaleApril 8, 2024 | globenewswire.comEyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial OpportunitiesApril 5, 2024 | reuters.comEyenovia IncApril 4, 2024 | msn.comLenz Therapeutics’ Eye Drop Helps Improve Vision in Late-Stage StudyApril 3, 2024 | globenewswire.comEyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare MeetingsMarch 30, 2024 | insidertrades.comStuart M. Grant Acquires 100,000 Shares of Eyenovia, Inc. (NASDAQ:EYEN) StockMarch 22, 2024 | marketbeat.comBrokers Set Expectations for Eyenovia, Inc.'s Q2 2024 Earnings (NASDAQ:EYEN)Eyenovia, Inc. (NASDAQ:EYEN - Free Report) - Research analysts at HC Wainwright issued their Q2 2024 earnings per share estimates for shares of Eyenovia in a report released on Tuesday, March 19th. HC Wainwright analyst M. Caufield expects that the company will earn ($0.19) per share for the quarMarch 21, 2024 | insidertrades.comEyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Acquires $61,500.00 in StockMarch 20, 2024 | marketbeat.comInsider Buying: Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Purchases 50,000 Shares of StockEyenovia, Inc. (NASDAQ:EYEN - Get Free Report) major shareholder Stuart M. Grant bought 50,000 shares of the stock in a transaction dated Tuesday, March 19th. The stock was bought at an average cost of $1.23 per share, for a total transaction of $61,500.00. Following the acquisition, the insider now directly owns 5,330,715 shares of the company's stock, valued at approximately $6,556,779.45. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.March 20, 2024 | seekingalpha.comEyenovia, Inc. (EYEN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | marketbeat.comEyenovia, Inc. (NASDAQ:EYEN) Short Interest UpdateEyenovia, Inc. (NASDAQ:EYEN - Get Free Report) saw a large increase in short interest during the month of February. As of February 29th, there was short interest totalling 2,890,000 shares, an increase of 8.2% from the February 14th total of 2,670,000 shares. Based on an average trading volume of 715,400 shares, the short-interest ratio is currently 4.0 days.March 19, 2024 | finanznachrichten.deEyenovia, Inc.: Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | markets.businessinsider.comEyenovia’s Strategic Commercial Synergy and Growth Potential Reinforce Buy RatingMarch 19, 2024 | finance.yahoo.comEyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | marketbeat.comEyenovia (NASDAQ:EYEN) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPSEyenovia (NASDAQ:EYEN - Get Free Report) released its earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.01. During the same quarter in the previous year, the business earned ($0.17) earnings per share.March 19, 2024 | marketbeat.comEyenovia (NASDAQ:EYEN) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Eyenovia in a report on Tuesday.March 19, 2024 | finance.yahoo.comQ4 2023 Eyenovia Inc Earnings CallMarch 18, 2024 | benzinga.comRecap: Eyenovia Q4 EarningsMarch 18, 2024 | investorplace.comEYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023March 18, 2024 | markets.businessinsider.comEyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comEyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 17, 2024 | msn.comEyenovia Q4 2023 Earnings PreviewMarch 17, 2024 | marketbeat.comEyenovia (EYEN) Scheduled to Post Quarterly Earnings on MondayEyenovia (NASDAQ:EYEN) will be releasing earnings after the market closes on Monday, March 18, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=573125)March 13, 2024 | globenewswire.comNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsMarch 12, 2024 | marketbeat.comEyenovia (EYEN) to Release Quarterly Earnings on MondayEyenovia (NASDAQ:EYEN) will be releasing earnings after the market closes on Monday, March 18, Zacks reports.March 12, 2024 | insidertrades.comInsider Buying: Eyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Purchases 10,717 Shares of StockMarch 11, 2024 | marketbeat.comEyenovia, Inc. (NASDAQ:EYEN) Major Shareholder Purchases $16,932.86 in StockEyenovia, Inc. (NASDAQ:EYEN - Get Free Report) major shareholder Stuart M. Grant acquired 10,717 shares of the business's stock in a transaction dated Friday, March 8th. The stock was purchased at an average cost of $1.58 per share, for a total transaction of $16,932.86. Following the transaction, the insider now owns 5,280,715 shares in the company, valued at $8,343,529.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.March 11, 2024 | markets.businessinsider.comEyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18thMarch 11, 2024 | globenewswire.comEyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18thMarch 7, 2024 | marketbeat.comFY2025 Earnings Forecast for Eyenovia, Inc. Issued By William Blair (NASDAQ:EYEN)Eyenovia, Inc. (NASDAQ:EYEN - Free Report) - William Blair decreased their FY2025 EPS estimates for shares of Eyenovia in a report issued on Tuesday, March 5th. William Blair analyst T. Lugo now anticipates that the company will earn ($1.55) per share for the year, down from their previous forecaMarch 6, 2024 | markets.businessinsider.comEyenovia, Formosa Gets FDA Approval For Clobetasol Propionate Ophthalmic Eye DropsMarch 6, 2024 | markets.businessinsider.comEyenovia’s Strategic Expansion: Dual Product Offering Enhances Market PositionMarch 6, 2024 | msn.comEyenovia falls despite FDA nod for pain therapyMarch 6, 2024 | finance.yahoo.comBeyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, InflammationMarch 5, 2024 | globenewswire.comEyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular SurgeryMarch 4, 2024 | reuters.comUS FDA approves Eyenovia's eye drug, Formosa Pharma saysMarch 4, 2024 | finance.yahoo.comUPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. EYEN Media Mentions By Week EYEN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYEN News Sentiment▼0.160.42▲Average Medical News Sentiment EYEN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYEN Articles This Week▼122▲EYEN Articles Average Week Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BOLT News Today VYNE News Today CARA News Today UNCY News Today NXTC News Today LEXX News Today SNSE News Today DRRX News Today JAN News Today CASI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYEN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
